Alkermes plc (ALKS) up 14.94% since start of the year

Alkermes plc (NASDAQ: ALKS) is 14.94% higher on its value in year-to-date trading and has touched a low of $20.46 and a high of $31.34 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALKS stock was last observed hovering at around $27.55 in the last trading session, with the day’s gains setting it 0.37% off its average median price target of $33.00 for the next 12 months. It is also 28.48% off the consensus price target high of $39.04 offered by 12 analysts, but current levels are -20.14% lower than the price target low of $23.24 for the same period.

Currently trading at $27.92, the stock is 7.39% and 13.80% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.18 million and changing 1.34% at the moment leaves the stock 4.92% off its SMA200. ALKS registered 15.60% gain for a year compared to 6-month loss of -8.04%. The firm has a 50-day simple moving average (SMA 50) of $2.61 and a 200-day simple moving average (SMA200) of $13.18.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 14.52% gain in the last 1 month and extending the period to 3 months gives it a 3.21%, and is 1.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.36% over the week and 3.02% over the month.

Alkermes plc (ALKS) has around 2280 employees, a market worth around $4.66B and $1.59B in sales. Current P/E ratio is 22.62 and Fwd P/E is 12.86. Profit margin for the company is 13.50%. Distance from 52-week low is 36.46% and -10.90% from its 52-week high. The company has generated returns on investments over the last 12 months (12.47%).

Alkermes plc (ALKS) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Alkermes plc (ALKS) is a “Overweight”. 12 analysts offering their recommendations for the stock have an average rating of 2.00, where 6 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Alkermes plc is expected to release its quarterly report on 02/15/2024.The EPS is expected to grow by 394.24% this year.

Alkermes plc (ALKS) Top Institutional Holders

The shares outstanding are 164.38M, and float is at 164.12M with Short Float at 4.74%.

Alkermes plc (ALKS) Insider Activity

A total of 22 insider transactions have happened at Alkermes plc (ALKS) in the last six months, with sales accounting for 11 and purchases happening 11 times. The most recent transaction is an insider sale by LAURENCIN CATO T,the company’sDirector. SEC filings show that LAURENCIN CATO T sold 2,638 shares of the company’s common stock on Jun 08 at a price of $31.85 per share for a total of $84020.0. Following the sale, the insider now owns 7479.0 shares.

Alkermes plc disclosed in a document filed with the SEC on Jun 07 that LAURENCIN CATO T (Director) sold a total of 2,800 shares of the company’s common stock. The trade occurred on Jun 07 and was made at $31.50 per share for $88200.0. Following the transaction, the insider now directly holds 7479.0 shares of the ALKS stock.

Still, SEC filings show that on May 30, Nichols Christian Todd (SVP, Chief Commercial Officer) disposed off 27,134 shares at an average price of $28.93 for $0.78 million. The insider now directly holds 40,984 shares of Alkermes plc (ALKS).

Alkermes plc (ALKS): Who are the competitors?

The company’s main competitors (and peers) include AstraZeneca PLC ADR (AZN) that is trading -2.49% down over the past 12 months. Johnson & Johnson (JNJ) that is -12.41% lower over the same period.